Document:

Exhibit 10.13

 

IMMUNOME, INC.

 

April 15, 2020

 

Re:          Immunome, Inc.
 – Consulting Arrangement

 

Dear Michael:

 

This letter agreement
contains the terms and conditions of your engagement as a consultant to Immunome, Inc. (the “Company”).

 

1.            Scope
of Engagement. You will serve as a consultant to the Company in connection with the project or projects described in Item
1 of Exhibit A (the “Project(s)”). You will render to the Company the consulting services in connection with the
Project(s) as the Company may from time to time reasonably request. Your time commitment for performance of the services is, to
the extent applicable, also described in Item 2 of Exhibit A.

 

2.            Compensation.
As consideration for your services, the Company will compensate you in the manner described in Item 3 of Exhibit A.

 

3.            Term.
The term of your engagement shall commence on the date identified above and continue until the sooner of the one-year anniversary
thereof or the date on which the Project(s) is/are completed; provided, however, that either party may terminate
this agreement at any time by giving the other 10 days’ advance written notice thereof in the manner described in paragraph
11 below.

 

4.            Confidentiality.

 

(a)       As
a condition to your engagement by the Company, you agree, during the term of this agreement and at all times thereafter, to hold
all “Confidential Information” (as defined below) in the strictest confidence and not to disclose or divulge any Confidential
Information to any person or entity or use any Confidential Information for any purpose whatsoever other than in the performance
of your consulting duties on behalf of the Company. You will take such security measures with respect to all Confidential Information
known or acquired by you as may be reasonably necessary to protect and preserve the confidentiality thereof.

 

(b)       “Confidential
Information” means any and all information relating to the business or operations of the Company or to the Project(s) not
generally known by others, including, but not limited to, proprietary technology, trade secrets, patented processes, research and
development activities and data, market studies and forecasts, competitive analysis, prevention and pricing policies, sales activities
or procedures, the substance of agreements with customers and others, marketing arrangements, customer credit or other financial
data, service and training programs and arrangements or customer lists, or any other proprietary or confidential information of
the Company or other parties with whom the Company has business relations concerning the business and activities of the Company
or of such other parties.

 

(c)       Notice
Concerning Immunity from Liability for Confidential Disclosure of a Trade Secret to the Government or in a Court Filing. You recognize
that the Defend Trade Secrets Act of 2016 provides that: (i) an individual shall not be held criminally or civilly liable under
any Federal or State trade secret law for the disclosure of a trade secret under the Act that: (A) is made - (1) in confidence
to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (2) solely for the purpose
of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit
or other proceeding, if such filing is made under seal; and (b) an individual who files a lawsuit for retaliation by an employer
for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret
information in the court proceeding, if the individual: (A) files any document containing the trade secret under seal; and (B)
does not disclose the trade secret, except pursuant to court order.

 

    1

     

    

 

5.            Work
Product. You acknowledge that all original works of authorship which are made by you (solely or jointly with others) within
the scope of your service to the Company and which are protectable by copyright are “works made for hire,” pursuant
to United States Copyright Act (17 U.S.C., Section 101). Without limitation of the foregoing, all Immunome specific related Work
Product shall be the sole property of the Company and you will disclose all Work Product to the Company promptly after it is generated.
To the extent any Work Product is not a “work made for hire” as aforesaid, you hereby assign to the Company, and this
agreement shall operate as an irrevocable and unconditional assignment by you to the Company of, all of your right, title and interest
in such Work Product in perpetuity. You agree to execute and deliver any and all instruments and other documents and take such
other actions as may be necessary or reasonably requested by the Company to document the aforesaid assignment and transfer of the
Work Product to the Company, or to enable the Company to secure, register, maintain, enforce or otherwise fully protect its rights
in and to the Work Product, in a timely manner. “Work Product” shall mean and include all Immunome specific related
work product, reports and deliverables created, developed, conceived, compiled or otherwise generated by you in connection with
a Project or otherwise as a result of tasks assigned by the Company.

 

7.            Other
Obligations. You represent and warrant to the Company that your execution of this agreement and performance of your duties
hereunder do not and will not violate the terms or conditions of any other agreement or understanding by which you are bound or
subject, and that you know of no basis for any claim that you are so bound or subject. You will not disclose to or use on behalf
of the Company any confidential or proprietary information belonging to any third party, unless written authorization from such
third party is first obtained. You will not undertake any other obligations, or perform any other services, to the extent that
doing so would conflict with your obligations to the Company.

 

9.            Relationship
of the Parties. You shall serve the Company as an independent contractor, and not as a partner, agent, servant or employee.
Under no circumstances shall you have, or hold yourself out as having, any right, power or authority to undertake, create or enter
into any obligation or contract in the name or on behalf of the Company or to bind the Company in any respect. You shall not be
entitled to receive any payments from the Company, by way of compensation, expenses, reimbursements or otherwise, except as specifically
provided herein, or to participate in or receive benefits under any employee benefit plans maintained or sponsored by the Company
or otherwise made available to the employees of the Company.

 

10.          Remedies.
The Company’s remedy at law for breach or threat of breach of this agreement is inadequate. The Company shall have the right
to injunctive relief in the event of any such breach or threatened breach, in addition to any other remedy available to the Company.
The existence of any claim or cause of action of any nature or description that you may have against the Company or any employee
or agent of the Company, whether predicated upon this agreement or otherwise, shall not constitute a defense to the enforcement
by the Company of the restrictive covenants contained herein, but shall be litigated separately.

 

11.          Notices.
All notices, requests, demands and other communication hereunder shall be made in writing and shall be deemed to have been duly
given if delivered or sent by Federal Express or other reputable overnight courier service, by electronic facsimile transmission,
or by prepaid certified mail, return receipt requested, if to the Company, addressed to the Chief Executive Officer of the Company
at the Company’s principal executive offices, and if to you, addressed to you at your address set forth on page one of this
agreement. Either party may change its or his address for notice hereunder by giving notice of change of address in the manner
herein provided.

 

    2

     

    

 

12.          Severability.
If any provisions of this agreement shall be invalid or unenforceable to any extent or in any application, then the remainder of
this agreement and of such term and condition, except to such extent or in such application, shall not be affected thereby, and
each and every term and condition of this agreement shall be valid and enforced to the fullest extent and in the broadest application
permitted by law. If the invalidity or unenforceability is due to the unreasonableness of the time or scope of any covenant or
restriction, said covenant and/or restriction nevertheless shall be effective for such period of time or within such scope as may
be determined to be reasonable by a court of competent jurisdiction.

 

13.          Waiver
of Breach. No delay or omission by the Company in exercising any right under this agreement shall operate as a waiver of that
right or of any other right. A waiver or consent given by the Company on any one occasion shall be effective only in that instance
and shall not be construed as a bar to or waiver of any right on any other occasion.

 

14.          Entire
agreement; Amendment. This agreement constitutes the entire agreement between the parties with respect to the subject matter
hereof and supersedes all prior agreements or understandings, written or oral, in respect thereof. This agreement may be amended,
modified, superseded, canceled, renewed or extended, and the terms and covenants hereof may be waived, only by a written instrument
signed by both of the parties hereto, or in the case of a waiver, by the party waiving compliance.

 

15.          Assignment
and Benefit. You may not assign, subcontract or delegate this agreement or your rights or obligations under this agreement,
and any attempt to do so is null and void. Subject to the preceding sentence, this agreement shall be binding upon and inure to
the benefit of the parties hereto and their respective executors, administrators, legal representatives, successors and assigns.

 

16.          Governing
Law. This agreement, and all questions arising in connection herewith, shall be governed by and construed in accordance with
the laws of the State of Delaware, USA.

 

Please indicate your acceptance
of and agreement to the foregoing terms and conditions of your engagement by signing below in the space provided. Upon your execution
hereof, this letter will become a binding agreement as of the date of execution.

 

	 	Very truly yours,
	 	 
	 	IMMUNOME, INC.
	 	 
	 	By: 	/s/ Purnanand Sarma
	 	 	Name: Purnanand Sarma
	 	 	Title: Chief Executive Officer

 

I HEREBY ACKNOWLEDGE THAT
I HAVE READ THE FOREGOING, AND THAT I UNDERSTAND AND AGREE TO EACH AND EVERY PROVISION.

 

 

	 	/s/ Michael Lefenfeld
	 	Signature of Consultant
	 	 
	 	Date: April 15, 2020

 

    3

     

    

 

CONSULTING AGREEMENT

 

EXHIBIT A

 

Item 1. Description of
the Project(s).

 

Assistance with pursuing
and negotiating federal contracts and grants.

 

Item 2. Time Commitment.

 

As mutually agreed by the
parties.

 

Item 3. Compensation.

 

A stock option grant for
66,666 shares, subject to Board approval.

 

    4Exhibit 10.14

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [***], HAS BEEN OMITTED BECAUSE IMMUNOME, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE
COMPETITIVE HARM TO IMMUNOME, INC. IF PUBLICLY DISCLOSED.

 

EXCLUSIVE LICENSE AGREEMENT

 

This Exclusive License Agreement (“Agreement”)
is made effective as of the 28th day of June, 2019 (“Effective Date”), by and between Arrayjet Limited, a company
incorporated in Scotland with registered number SC209936 and having its registered office at Stobo House, Pentlandfield, Roslin,
Midlothian, EH25 9RE (“ARRAYJET”), and Immunome, Inc., a corporation organized and existing under the laws of
the State of Delaware, USA with an address at 665 Stockton Drive, Suite 300, Exton, PA 19341 (“Licensee”).

 

WHEREAS, ARRAYJET exclusively owns certain
Licensed Patents and Licensed Know-how, as defined below, and is willing to grant a license to Licensee under them pursuant to
the terms of this Agreement herein below (the “License”).

 

NOW, THEREFORE, in consideration of the
representations, covenants, warranties and agreements set forth below, the parties agree as follows:

 

Section 1.                  
Definitions. For the purpose of this Agreement, the Appendix A definitions will apply.

 

Section 2.                  
Grant.

 

A.               
License. ARRAYJET hereby grants to Licensee an exclusive, assignable (to the extent this Agreement is assignable),
sublicensable (as expressly contemplated by this Agreement) License under the Licensed Patents and Licensed Know-how to practice
and use the same for any and all purposes, including, without limitation, to research, develop, make, have made, use, sell, offer
for sale, market, and otherwise commercialize Products, solely in Immunome’s Area of Interest (as defined in Appendix A)
in the Licensed Field and Licensed Territory. The Licensee hereby acknowledges and agrees that, subject to the terms of this Agreement,
ownership of the Licensed Know-how and Licensed Patents shall vest exclusively with ARRAYJET.

 

The Licensee shall use reasonable endeavors,
and take all reasonable commercial steps, to procure that, so far as is legally permissible:

 

(i)               
all Licensee IPR and Licensee Results made by any employees of the Licensee or independent contractors or others engaged
by the Licensee on any project from which the Licensee IPR or Licensee Results derive, or which may vest in any participants in
any of the trials or studies carried out by the Licensee in respect of the Licensed Patents and Licensed Know-how shall vest in
or be assigned to the Licensee;

 

(ii)              
all employees of, and independent contractors and others engaged by, the Licensee shall execute and do all acts and things
reasonably necessary to vest Licensee IPR and Licensee Results in, and assign Licensee IPR and Licensee Results to, Licensee; and

 

(iii)            
all Licensee IPR and Licensee Results shall be disclosed in writing to ARRAYJET promptly after they have been made.

 

    1

     

    

 

B.                 
 Sublicenses.

 

(i)                
Sublicensing Right. The Licensee may grant to third parties written, nonexclusive sublicenses, without the right
to further sublicense, under Licensee’s rights under clause 2A. All such sublicenses shall: (a) contain terms and conditions
no less restrictive than, no less protective of ARRAYJET’s rights than, and consistent with, those set forth in this Agreement;
and (b) state that the sublicense is subject to the termination of this Agreement. No sublicense shall purport to grant any rights
that extend beyond the scope of rights granted to Licensee under this Agreement.

 

(ii)              
Access to Sublicensing Information. The Licensee shall promptly provide ARRAYJET with the name, contact information,
and address of each sublicensee, as well as information regarding the number of full-time employees of each such sublicensee to
allow ARRAYJET to determine whether it is eligible for small entity filing status for patent prosecution and maintenance purposes.
Thereafter, Licensee shall deliver to ARRAYJET annual reports, within [***] after each March 1 during the term of this Agreement,
summarizing the licensed technology-relevant business and research activities of each sublicensee and containing sufficient details
regarding the sublicensees’ business relating to the Licensed Patents to assess when, whether, and the extent to which each
sublicensee may be practicing its sublicensed rights. In addition, upon ARRAYJET’s written request Licensee shall provide
to ARRAYJET copies of each sublicense agreement and any amendments thereto. Licensee will ensure that ARRAYJET has audit rights
for each sublicense agreement of the same scope as provided in clause 6 hereof with respect to Licensee, and shall include appropriate
terms providing for such audit rights in all sublicense agreements.

 

C.                 
Reservation of Rights. ARRAYJET hereby reserves, pending consultation and agreement with the Licensee, the right
to grant non-profit research institutions and governmental agencies non-exclusive licenses to practice and use the inventions of
the Licensed Patents for Non-Commercial Research Purposes. Licensee agrees that it will not unduly or unreasonably prevent the
granting of such non-exclusive licenses.

 

D.                
New Intellectual Property Rights. ARRAYJET shall disclose to Licensee any Intellectual Property Rights ARRAYJET pursues
or acquires in technology related to the Licensed Patents and Licensed Know-how that are not included in the Licensed Patents and
Licensed Know-how (“New Intellectual Property Rights”), and ARRAYJET shall negotiate in good faith (including
as to any additional costs that may be due and payable by the Licensee to ARRAYJET in respect of any New Intellectual Property
Rights) with Licensee to add such New Intellectual Property Rights to the License under this Agreement within the [***] period
following such disclosure (unless extended by mutual agreement of the parties).

 

Section 3.                  
Development.

 

A.                
The Licensee agrees to, represents and warrants that it will diligently utilize the Licensed Patents and Licensed Know-how
to develop Immunome’s Area of Interest within the terms of this Agreement

 

B.                 
Where any marketable Products are developed by the Licensee in the future, the Licensee agrees to, represents and warrants
that it will, subject to Licensee’s reasonable commercial judgment, diligently develop, seek any necessary regulatory approval
for, manufacture, market, and sell Products in each Licensed Field and Licensed Territory throughout the term of this Agreement,
and subject to the payment of the fees set out in this Agreement.

 

    2

     

    

 

C.                 
 Beginning in calendar year 2020, Licensee will provide ARRAYJET with a written annual Development Report summarizing its
development activities since the last Development Report. Licensee will submit Development Reports on an annual basis within [***]
of March 1 of each calendar year.

 

Licensee’s books and records regarding
its development activities with respect to the Licensed Patents will be subject to the obligations and audit procedures set forth
in clause 6.

 

D.                
Beginning in calendar year 2020, ARRAYJET will provide Licensee with a written annual report summarizing its research license
activity (as permitted under clause 2C) and its other licensing activities (as set forth in clause 6C).

 

Section 4.                  
Consideration.

 

A.                
Exclusivity Fee.

 

(i)                
As of the Effective Date, no further fees shall be payable by the Licensee to ARRAYJET in accordance with clauses 12.3 and
12.4 of the MSA. For the avoidance of doubt, this clause 4A (inclusive) shall be to the exclusion of and in full substitution of
clauses 12.3 and 12.4 of the MSA.

 

(ii)              
Subject to the payment by Licensee of the annual fee set out at clause 4A(iii) below (the “Exclusivity Fee”),
ARRAYJET shall grant to Licensee exclusive use of the License in relation to Immunome’s Area of Interest and in the Licensed
Territory and it shall not grant to any third party any license for use of the Licensed Patents where such use would relate to
Immunome’s Area of Interest for the duration of this Agreement (“Exclusivity”).

 

(iii)            
The fee for the first year of Exclusivity shall be paid in full and in cleared funds to ARRAYJET within [***] of the Effective
Date of this Agreement (the “First Exclusivity Fee”). It is agreed by the Licensee that the First Exclusivity
Fee shall be payable in full to ARRAYJET on the terms of this Agreement and shall be non-refundable. Thereafter, beginning with
the second year of Exclusivity, the Exclusivity Fee shall be payable in equal quarterly installments and become due and payable
to ARRAYJET in cleared funds on or within [***] of the end of each quarter for the duration of this Agreement and subject to the
provisions of this clause 4A(iii), 4A(iv) and 4A(v) (the “Recurring Exclusivity Fee”).

 

(iv)             
The amount of the First Exclusivity Fee shall be $150,000, payable in accordance with clause 4A(iii) above (the “Exclusivity
Start Date”). Thereafter, the Recurring Exclusivity Fee shall be payable in equal quarterly installments (in accordance
with clause 4A(iii)) and shall be:

 

		(1)	[***] for the second year, payable in accordance with clause 4A(iii) (i.e., 4 quarterly installments of [***]); and

 

		(2)	[***] for the third year and each year thereafter payable in accordance with clause 4A(iii) for the duration of this Agreement
(i.e., 4 quarterly installments of [***]).

 

See Appendix
F for a detailed example of fee payment.

 

    3

     

    

 

(v)               
 The payment of any outstanding portion of the Exclusivity Fee after termination of this Agreement shall be paid pro-rata
from the period of the last installment of the Exclusivity Fee being paid and the date of termination of this Agreement.

 

B.                 
License Fee.

 

(i)                
If Licensee purchases instrumentation from ARRAYJET and undertakes screening for Products on its own (as opposed to having
screening services provided by ARRAYJET under the MSA), Licensee agrees to pay to ARRAYJET an annual license fee of [***] (the
 “License Fee”) for as long as Licensee uses such instrumentation (and replacement instrumentation provided by
ARRAYJET, for which the Licensee accepts that there may be an additional cost chargeable by ARRAYJET to the Licensee). The License
Fee shall become due and payable to ARRAYJET in equal quarterly installments not more than [***] after the end of each quarter
for the duration of this Agreement. The first installment of the first License Fee shall be paid by the Licensee to ARRAYJET on
the first anniversary of the Installation Acceptance Date (for the avoidance of doubt, there shall be no License Fee payable for
the first year following the Installation Acceptance Date).

 

See Appendix
F for a detailed example of fee payment.

 

(ii)              
The payment of any outstanding portion of the License Fee beyond the duration of the Agreement shall be paid pro-rata from
the period of the last installment of the License Fee being paid and the date of termination of this Agreement.

 

C.                 
Sublicense Fee.

 

(i)                
If Licensee purchases instrumentation from ARRAYJET and undertakes screening for Products on its own for a third-party sublicensee
(as opposed to having screening services provided by ARRAYJET under the MSA), with respect to each such sublicensee to whom Licensee
provides screening services, Licensee will pay to ARRAYJET an annual fee of [***] (the “Sublicense Fees”) for
as long Licensee uses such instrumentation (and replacement instrumentation provided by ARRAYJET) to provide screening services
to each such sublicensee. The Sublicense Fees shall be payable by the Licensee to ARRAYJET in respect of each and every individual
customer to whom the Licensee provides screening services, and reasonable written notice shall be provided to ARRAYJET where the
Licensee undertakes to provide any such third-party screening services. The Sublicense Fees shall become due and payable to ARRAYJET
in cleared funds upon the Licensee’s execution of a screening services agreement and then on each and every anniversary of
the effective date of the screening services agreement, for the duration of this Agreement, in respect of each such sublicensee.
The Licensee agrees that it shall not enter into any such screening services agreement that would limit the scope, validity or
enforcement of the Licensed Patents or this Agreement, without the prior written consent of ARRAYJET. ARRAYJET shall not be liable
for any damages, loss, or costs incurred by the Licensee or respective sublicensee or third party in respect of the Licensee providing
such third party screening services via a sublicense. For the avoidance of doubt, Sublicense Fees shall not be due and payable
on any sublicense granted by Licensee that does not implicate Licensee’s providing screening services to such sublicensee
using instrumentation provided by ARRAYJET to Licensee, ARRAYJET being fully compensated for such other sublicenses through Licensee’s
payment of, e.g., earned royalties and sublicensing royalties hereunder.

 

See Appendix
F for a detailed example of fee payment.

 

    4

     

    

 

D.                 Royalty.
Licensee agrees to pay to ARRAYJET as “earned royalties” a royalty calculated as a percentage of Licensee’s
and its sublicensees’ Net Sales of Products in accordance with the terms and conditions of this Agreement. The royalty
will remain fixed while this Agreement is in effect at the rate of [***] of the Net Sales of Products of Licensee and its
sublicensees. The royalty is deemed earned as of the earliest of the date (i) Licensee receives payment for the transfer of
the Product, or (ii) the Product is transferred to a third party without charge. For the avoidance of doubt, on sales between
or among Licensee, its affiliates, and sublicensees for resale, the royalty shall be earned and paid by Licensee on the Net
Sales of the subsequent resale by the Licensee, its affiliates, or sublicensees, as appropriate, and not on the sales between
or among Licensee, its affiliates, and sublicensees. Notwithstanding the foregoing, if Licensee or a sublicensee is obligated
to pay Third Party Royalties, then Licensee may deduct [***] of the consideration paid to such third party in connection with
such Third Party Royalties from any royalties due to ARRAYJET under this Agreement, provided that:

 

(i)                
on an ongoing basis and prior to reduction of any royalty for a given calendar quarter, Licensee first provides written
evidence to ARRAYJET of the Licensee’s or a sublicensee’s obligation to pay a third party such Third Party Royalties;
and

 

(ii)              
in no event shall royalties due to ARRAYJET in any reporting period be so reduced to less than [***] of the amount that
would otherwise be due to ARRAYJET under this Agreement.

 

E.                 
Sublicensing Revenue. If Licensee receives any research fees, minimum royalties, or other research payments in consideration
for any rights granted under a sublicense, or option to sublicense, or other similar rights, and such payments are not based directly
upon the amount or value of Products sold by the sublicensee (“Sublicensing Revenue”), then Licensee will pay
ARRAYJET [***] of such Sublicensing Revenue within [***] of receipt of such Sublicensing Revenue, and otherwise in the manner specified
in clause 4G, with the amounts due to ARRAYJET being deemed earned as of the date they are received by Licensee. Licensee will
not receive from its sublicensees anything of value in lieu of cash payments in consideration for any sublicense granted under
this Agreement without the express prior written consent of ARRAYJET. Additionally, Licensee will not agree to postpone the payment
date of any Sublicensing Revenue in exchange for any payment or other consideration not itself accounted for as part of the Sublicensing
Revenue. No payments owed to ARRAYJET under this clause E will be prorated, whether the sublicense to the Licensed Patents is bundled
with other licenses or sublicenses or not, without ARRAYJET’s written consent.

 

F.                 
Patent Prosecution and Costs.

 

(i)                
Licensee agrees to reimburse ARRAYJET for pro-rated costs, equitably shared by Licensee and any other licensees of the Licensed
Patents (in all fields of use) on a patent/patent application-by-patent/patent application basis, incurred by ARRAYJET in filing,
prosecuting and maintaining the Licensed Patents (“Patent Costs”), including those Patent Costs incurred prior
to (“Past Patent Costs”) and after (“Future Patent Costs”) the Effective Date, only where
such Patent Costs are incurred by virtue of the Licensee requiring ARRAYJET to file, prosecute, or maintain the Licensed Patents
in any jurisdiction within the Licensed Territory. Any Patent Costs due in accordance with this clause F(i) shall become due and
payable to ARRAYJET within [***] of receiving an invoice from ARRAYJET. Any country for which ARRAYJET files for such patent protection
at Licensee’s request and expense shall be included in the Licensed Territory under this Agreement. ARRAYJET reserves the
right to file a patent application (including a foreign filing or any continuing U.S. application), at its own expense, in any
countries not requested by Licensee pursuant to this clause 4F(i).

 

    5

     

    

 

(ii)               Unless
Licensee is in breach of any term or condition of this Agreement (including, without limitation for failure to timely
reimburse ARRAYJET for Patent Costs hereunder), ARRAYJET will prosecute all applications it files at Licensee’s
reasonable request pursuant to this clause 4F, and will consider any reasonable comments or suggestions by Licensee with
respect thereto, unless ARRAYJET determines that prosecution is unlikely to result in the issuance of a patent. ARRAYJET will
instruct its patent counsel to copy Licensee on relevant and applicable correspondence related to the Licensed Patents and to
interact with Licensee with respect to the preparation, filing, prosecution and maintenance of the Licensed Patents. ARRAYJET
will use reasonable efforts not to allow any Licensed Patents to lapse or become abandoned without Licensee’s written
authorization under this Agreement, except for filing of continuations, divisionals, or the like that substitute for a lapsed
application, provided that, ARRAYJET shall have no requirement to file, prosecute, or maintain Licensed Patents if Licensee
is not current with the Patent Cost obligations as set forth in this Agreement. If ARRAYJET decides to abandon prosecution or
maintenance of any patent or patent application under the Licensed Patents which Licensee has requested ARRAYJET to make and
maintain, ARRAYJET shall provide Licensee notice of ARRAYJET’s intent to abandon such application or patent and hereby
assigns such application or patent Licensee, and ARRAYJET shall take all reasonable steps to effect, formalize, and perfect
such assignment, as requested by Licensee.

 

G.                
Accounting; Payments. Amounts owed to ARRAYJET under clauses 4A, 4B, 4C, 4D and 4E will be paid on a quarterly basis,
with such amounts due and received by ARRAYJET on or around the following respective dates, as applicable in respect of the quarter
in which such amounts were earned: March 31, June 30, September 30 or December 31 in which such amounts were earned. A full accounting
showing how such amounts have been calculated will be submitted to ARRAYJET by the Licensee on the date of each such payment. For
royalties, such accounting will be on a per country and product line, model, or tradename basis and will be summarized on the form
shown in Appendix C of this Agreement, which will include a quarterly royalty forecast. In the event no payment is owed to ARRAYJET,
a statement setting forth that fact will be supplied to Licensee. Any payments not made when due will bear interest at the lower
of (a) the Prime Rate published in the Wall Street Journal plus 200 basis points, or (b) the maximum rate permitted by law. However,
in no event will this interest provision be construed as a grant of permission for any payment delays. (ii) Except as otherwise
directed, all amounts owing to ARRAYJET under this Agreement will be paid in U.S. dollars via wire transfer. All banking charges
will be paid for by the Licensee. All royalties and fees stated in currencies other than U.S. dollars will be converted at the
rate that is the arithmetic average of the rate shown in the Wall Street Journal, New York Edition on the last business day of
each month of the calendar quarter on the day preceding the payment due date.

 

Section 5.                  
Certain Warranties.

 

A.                
ARRAYJET warrants that it is the sole and exclusive owner of the Licensed Patents and Licensed Know-how or otherwise has
the right to grant the licenses granted to Licensee in this Agreement. However, nothing in this Agreement will be construed as:
(i) a warranty or representation by ARRAYJET as to the validity or scope of any of the Licensed Patents; (ii) a warranty or representation
that any product or process made, used, sold, or otherwise disposed of under or in association with the license granted in this
Agreement is or will be free from any claim of infringement or misappropriation of any intellectual property rights other than
the Licensed Patents; or (iii) an obligation to furnish any know-how not provided in the Licensed Patents or Licensed Know-how,
or any services other than those specified in this Agreement.

 

B.                 
Each party represents and warrants to the other party that, as of the Effective Date:

 

(i)                
such party is duly organized and validly existing under the laws of the jurisdiction of its incorporation or organization;

 

    6

     

    

 

(ii)              
 such party has taken all action necessary to authorize the execution and delivery of this Agreement and the performance
of its obligations under this Agreement;

 

(iii)            
this Agreement is a legal and valid obligation of such party, binding upon such party and enforceable against such party
in accordance with the terms of this Agreement, except as enforcement may be limited by applicable bankruptcy, fraudulent conveyance,
insolvency, reorganization, moratorium and other laws relating to or affecting creditors’ rights generally and by general
equitable principles; and

 

(iv)             
such party has all right, power and authority to enter into this Agreement and to perform its obligations under this Agreement.

 

C.                 
NEITHER PARTY MAKES ANY REPRESENTATIONS NOR EXTENDS ANY WARRANTIES OF ANY KIND WHATSOEVER, EITHER EXPRESS OR IMPLIED, INCLUDING
ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, MARKETABILITY, REGULATORY APPROVAL, SAFETY,
OR ACCURACY. NEITHER PARTY ASSUMES ANY RESPONSIBILITIES NOR MAKES ANY PROMISES WHATSOEVER WITH RESPECT TO THE USE, SALE, OR OTHER
DISPOSITION BY LICENSEE, ITS SUBLICENSEE(S), OR THEIR VENDEES OR OTHER TRANSFEREES, OF PRODUCTS OR ANY OTHER PRODUCTS OR SERVICES
EMPLOYING, EMPLOYED IN, INCORPORATING, OR MADE BY USE OF INVENTIONS LICENSED UNDER THIS AGREEMENT.

 

Section 6.                  
Recordkeeping.

 

A.                
Licensee and its sublicensee(s) will keep books and records sufficient to verify the accuracy and completeness of Licensee’s
and its sublicensee(s)’s commercialization activities and accounting referred to above, including, without limitation, invoices
for studies advancing the development of Products, laboratory notebooks, internal job cost records, inventory, purchase, and invoice
records relating to the Products or their development or manufacture. Such books and records will be preserved for a period not
less than [***] after they are created during and after the term of this Agreement.

 

B.                 
Licensee and its sublicensee(s) will take all steps necessary so that ARRAYJET may, via an ARRAYJET employee, attorney or
registered CPA designee (as reasonably agreed by the parties) and upon reasonable notice and during regular business hours within
[***] of its request, review all the books and records at a single U.S. location to allow ARRAYJET to verify the accuracy of Licensee’s
royalty reports and Development Reports, the royalty reports of its sublicensee(s), and any applicable Sublicense Fees. If a payment
deficiency is determined, Licensee and its sublicensee(s), as applicable, will pay the deficiency outstanding within [***] of receiving
written notice thereof, plus interest on outstanding amounts as described in clause 4G. In cases where the deficiency exceeds the
lesser of [***] of the royalties paid for that year or [***], then Licensee or its sublicensee(s) will be responsible for paying
ARRAYJET’s out-of-pocket expenses incurred with respect to such review.

 

C.                  ARRAYJET
will keep books and records sufficient to verify with the Licensee other existing license agreements that it has entered into
to ensure transparency in the business relationship. Such books and records will be preserved for a period not less than
[***] after they are created during and after the term of this Agreement. ARRAYJET and its third-party licensee(s) will take
all steps necessary so that Licensee may, via a License employee, attorney or registered CPA designee (as reasonably agreed
by the parties) and upon reasonable notice and during regular business hours within [***] of its request, review all the
books and records at a single location to allow Licensee to verify ARRAYJET’s reports relating to such third-party
license agreements.

 

    7

     

    

 

Section 7.                  
Term and Termination.

 

A.                
The term of the License and Agreement will begin on the Effective Date and continue until the earliest of the date that:
(1) this Agreement is terminated as provided for herein; (2) the payment of earned royalties under clause 4D, once begun, ceases
for more than one calendar year; and (3) the last of the Licensed Patents expires or is revoked, invalidated, held unenforceable,
disclaimed, dedicated to the public, abandoned, or otherwise terminated; provided, however, that following the termination of this
Agreement as provided in (3), the License rights with respect to Licensed Know-how shall continue perpetually (and without any
continued obligation of fees or royalties due to ARRAYJET).

 

B.                 
Licensee may terminate this Agreement at any time by giving at least [***] written and unambiguous notice of such termination
to ARRAYJET, which will include a statement of the reasons for termination. ARRAYJET may terminate this Agreement upon [***] written
notice to Licensee if Licensee, either directly or through a sublicensee, fails to achieve at least one of the following by the
fifth (5th) anniversary of Effective Date: (1) the Date of First Commercial Sale or (2) demonstration that there are at least three
different Products actively undergoing clinical trials for which ARRAYJET would be entitled to earn royalties as specified in clause
4D.

 

C.                 
If Licensee at any time defaults in the timely payment of any monies due to ARRAYJET, fails to timely provide to ARRAYJET
any Development Report or provides any false information with respect thereto, or commits any material breach of any other covenant,
representation, or warranty herein contained, and Licensee fails to remedy any such material breach or default within [***] after
written notice thereof by ARRAYJET, or if Licensee commits any act of bankruptcy, becomes insolvent, is unable to pay its debts
as they become due, files a petition under any bankruptcy or insolvency act, or has any such petition filed against it which is
not dismissed within [***], ARRAYJET may, at its option, terminate this Agreement immediately by giving notice of termination to
Licensee. If ARRAYJET commits any material breach of any covenant, representation, or warranty herein contained, and fails to remedy
any such material breach within [***] after written notice thereof by Licensee, or if ARRAYJET commits any act of bankruptcy, becomes
insolvent, is unable to pay its debts as they become due, files a petition under any bankruptcy or insolvency act, or has any such
petition filed against it which is not dismissed within [***], Licensee may, at its option, terminate this Agreement immediately
by giving notice of termination to ARRAYJET. The parties agree that termination pursuant to this clause C is a remedy to be invoked
only if the material breach, default, or other circumstance cannot be adequately remedied through a combination of specific performance
and the payment of money damages.

 

D.                
Upon the effective termination of this Agreement, Licensee and its sublicensee(s) will remain obligated to provide an accounting
for and to pay to ARRAYJET within [***] of termination all amounts owed under this Agreement, including without limitation royalties
earned up to the date of the termination, which amounts will be prorated, as applicable, as of the date of termination by the number
of days elapsed in the applicable calendar year.

 

E.                 
Waiver by either party of a single breach or default, or a succession of breaches or defaults, will not deprive such party
of any right to terminate this Agreement in the event of any subsequent breach or default.

 

    8

     

    

 

F.                 
 Assignment of Licensee’s Rights Upon A Sale.

 

(i)                
The Licensee may, with prior written notice to ARRAYJET, assign its rights and obligations under this Agreement to any person
or entity to which it transfers its business, or that part of its business to which this Agreement relates, provided that the assignee
undertakes in writing to ARRAYJET to be bound by Licensee’s obligations under this Agreement.

 

(ii)              
ARRAYJET may assign its rights and obligations under this Agreement to any person or entity to which it transfers its business,
or that part of its business to which this Agreement relates, provided that ARRAYJET gives reasonable written notice of such assignment
to the Licensee and that the assignee undertakes in writing to Licensee to be bound by ARRAYJET’s obligations under this
Agreement.

 

(iii)            
In the event of a sale of the whole or a significant part of the Licensee (whether by way of share or asset sale), all payments
due and owing under Section 4 up to the date of that sale (including payment(s) in respect of the year during which that date falls)
shall become payable immediately to ARRAYJET by the party to whom Licensee’s rights and obligations have been assigned, under
part (i) of this clause.

 

(iv)             
In the event of a sale of the whole of a significant part of ARRAYJET (whether by way of share or asset sale), all payments
due and owing under clause 4 shall continue to the party to whom ARRAYJET’S rights are assigned pursuant to paragraph (ii)
of this clause.

 

(v)               
Except as otherwise provided above, in no event shall ARRAYJET assign, transfer or delegate (voluntarily or involuntarily)
this Agreement, or any of its rights or obligations hereunder, without the prior written consent of Licensee (such consent not
unreasonably withheld), and any attempt to do so without such consent is null and void.

 

G.                
Licensee may terminate its rights in, and obligations with respect to individual patents and patent applications included
in the Licensed Patents by providing written notice to ARRAYJET (“Patent Termination Notice”). Termination of
Licensee’s rights in and obligations with respect to such patents and patent applications will be effective [***] after ARRAYJET’s
receipt of such Patent Termination Notice. ARRAYJET will use reasonable efforts to curtail Patent Costs chargeable to Licensee
under this Agreement with respect to patents and patent applications subject to a Patent Termination Notice after receipt of the
Patent Termination Notice.

 

H.                
Termination of this Agreement shall not relieve the parties of any obligation or 1iability that, at the time of termination,
has already accrued hereunder, or which is attributable to a period prior to the effective date of such termination. Termination
of this Agreement shall not preclude either party from pursuing all rights and remedies it may have hereunder or at law or in equity
with respect to any breach of this Agreement nor prejudice either party’s right to obtain performance of any obligation.
Notwithstanding the termination of this Agreement, the following provisions shall survive: Section 7; Section 12, part B; Section
14; Section 15; Section 16; and Section 17.

 

I.                   
If this Agreement is terminated for any reason, all outstanding sublicenses not in default and not terminated by their terms
will be assigned by Licensee to ARRAYJET, and such assignments will be accepted by ARRAYJET. Each assigned sublicense will remain
in full force and effect with ARRAYJET as the licensor or sublicensor instead of Licensee.

 

    9

     

    

 

Section 8.                  
RESERVED

 

Section 9.                  
Enforcement and Defense.

 

A.                
ARRAYJET shall use reasonable commercial endeavors to protect the Licensed Patents against infringers or otherwise act to
eliminate infringement, when, in ARRAYJET’s sole judgment, such action may be necessary, proper, and justified and makes
reasonable business sense considering all factors. In the event that Licensee or its sublicensee(s) believe there is infringement
of any Licensed Patent under this Agreement which is to its substantial detriment, Licensee will provide ARRAYJET with notification
and reasonable evidence of such infringement. Upon request by ARRAYJET, Licensee will provide ARRAYJET with such assistance and
information as may be useful to ARRAYJET in connection with ARRAYJET’s taking such action (if the cause of action arose during
the term of this Agreement and ARRAYJET reimburses Licensee for Licensee’s reasonable out-of-pocket expenses). For clarity,
in no event will Licensee or any sublicensee have the right to demand that ARRAYJET initiate or join in any suit for infringement.
ARRAYJET shall defend the Licensed Patents against challenges, including challenges to the validity or enforceability of the Licensed
Patents, whether made in the context of litigation, a petition to a governmental patent office, or otherwise, when, in ARRAYJET’s
sole judgment, such action may be necessary, proper, and justified and makes reasonable business sense considering all factors.

 

B.                 
If ARRAYJET fails to enforce or defend the Licensed Patents, then during the period in which, and in the jurisdiction where,
Licensee has exclusive rights under this Agreement and is the sole Licensee under the Licensed Patents, Licensee may, where it
believes that such action may be necessary, proper and justified and makes reasonable business sense considering all factors, institute
suit for patent infringement or defend the Licensed Patents against the infringer or challenger after providing ARRAYJET (a) a
written estimate of the expenses that would be reasonably incurred in connection with such action, including an estimate from two
outside law firms regarding the legal costs associated with such suit and (b) financial records reasonably sufficient to reasonably
demonstrate that Licensee has the financial wherewithal to pay such expenses as they fall due through the conclusion of such suit
by means of judgment or other final non-appealable decision. ARRAYJET may voluntarily join such suit, or be compelled to join such
suit if necessary to assert or maintain the suit, at Licensee’s reasonable expense, but may not thereafter commence suit
against the infringer for the acts of infringement that are the subject of Licensee’s suit or any judgment rendered in such
suit. ARRAYJET shall not unreasonably withhold, condition, or delay consent to being joined to such a suit. Licensee shall, with
the consent of ARRAYJET (where such settlement, consent judgement or voluntary disposition is relevant to ARRAYJET’s business
or rights under this Agreement), be free to enter into a settlement, consent judgment or other voluntary disposition, provided
that, any settlement, consent judgment or other voluntary disposition (i) does not limit the scope, validity or enforcement of
the Licensed Patents or (ii) does not admit fault or wrongdoing on the part of ARRAYJET, or where such an admission is made it
must be approved in advance by ARRAYJET in writing. Licensee’s request for such approval shall include complete copies of
final settlement documents, a detailed summary of such settlement, and any other information material to such settlement. ARRAYJET
shall provide Licensee notice of its approval or denial within [***] of any request for such approval by Licensee, provided that
(y) in the event ARRAYJET wishes to deny such approval, such notice shall include a detailed written description of ARRAYJET’s
reasonable objections to the proposed settlement, consent judgment, or other voluntary disposition and (z) ARRAYJET shall be deemed
to have approved of such proposed settlement, consent judgment, or other voluntary disposition in the event it fails to provide
such notice within such [***] period in accordance herewith.

 

C.                  Any
recovery or settlement received in connection with any suit will first be shared by ARRAYJET and Licensee equally to cover
any costs each incurred and next shall be paid to ARRAYJET or Licensee to cover any costs it incurred in excess of the costs
of the other (including any costs incurred by Licensee on behalf of ARRAYJET). Any remaining recoveries shall be allocated as
follows:

 

    10

     

    

 

(i)                
for any suit that is initiated by either party and in which both parties participated at their own cost and expense, the
parties shall split the remainder evenly (50/50); and

 

(ii)              
for any suit that is initiated by Licensee and in which ARRAYJET was not a party or in which ARRAYJET was a party with its
costs and expenses paid by Licensee, ARRAYJET shall receive [***] of the recovery and the Licensee shall receive the remainder;
and

 

(iii)            
for any suit that is initiated by ARRAYJET and in which Licensee does not participate as a party, ARRAYJET shall receive
[***].

 

Section 10.              
Patent Marking. Licensee and its sublicensee(s) will mark all Products or Product packaging or advertising and invoices
in the case of Products that are services with the appropriate patent number reference in compliance with the requirements of 35
U.S.C. § 287.

 

Section 11.              
Product Liability; Conduct of Business.

 

A.                
Licensee will, at all times during the term of this Agreement and thereafter, indemnify, defend, and hold harmless the inventors
of the Licensed Patents, ARRAYJET, and their respective employees, trustees, and agents against all claims and expenses, including
legal expenses and reasonable attorneys’ fees, arising out of third-party claims relating to (i) the death of or injury to
any person or persons or any damage to tangible property or (ii) any other claim, proceeding, demand, expense, loss, and liability
of any kind whatsoever resulting from each of the following: (1) the development, design, production, manufacture, sale, use, lease,
consumption, marketing, import/export, or advertisement of Products, (2) the exercise of any right or the performance or non-performance
of any obligation of Licensee or its sublicensee(s) hereunder, or (3) the negligent, reckless, or willful actions or omissions
of Licensee. ARRAYJET at all times reserves the right to select and retain counsel of its own, at its own cost, to defend ARRAYJET’s
interests.

 

B.                 
Licensee warrants that it will, on or before the launch of its first Product, maintain and will continue to maintain liability
insurance coverage appropriate to the risk involved in marketing the Products subject to this Agreement. Upon ARRAYJET’s
request, Licensee will present evidence to ARRAYJET that such coverage is being maintained.

 

C.                 
LIMITATION OF LIABILITY. IN NO EVENT SHALL EITHER PARTY OR ANY OF ITS AFFILIATES BE LIABLE TO THE OTHER PARTY OR
ANY OF ITS AFFILIATES FOR SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING LOSS OF PROFITS, WHETHER
IN CONTRACT, WARRANTY, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY OR OTHERWISE ARISING OUT OF OR RELATING TO THIS AGREEMENT,
THE TRANSACTIONS CONTEMPLATED HEREIN OR ANY BREACH HEREOF.

 

Section 12.              
Publicity and Non-solicitation.

 

A.                
Use of Names. Neither Licensee nor its sublicensee(s) will use ARRAYJET’s name, or any derivation thereof,
nor the name of any inventor of the Licensed Patents, in sales promotion, advertising, or any other form of publicity without the
prior written approval of the entity or person whose name is being used.

 

    11

     

    

 

B.                 
 Restrictive Covenant. For the term of this Agreement and for a period of [***] after the end of the Agreement, Licensee
shall not:

 

(i)                
knowingly employ or engage an employee or consultant of ARRAYJET, without ARRAYJET’s prior written consent;

 

(ii)              
knowingly induce or seek to induce any person employed or engaged as a consultant of ARRAYJET to leave their employment
or consultancy with ARRAYJET;

 

Section 13.                
RESERVED

 

Section 14.                
Notices. Any notice required to be given pursuant to the provisions of this Agreement will be in writing and will
be deemed to have been given at the earlier of the time when actually received as a consequence of any effective method of delivery,
including but not limited to hand delivery or electronic transmission, i.e., email, transmission by telecopier or delivery by a
professional courier service or the time when sent by certified or registered mail addressed to the party for whom intended at
the address below or at such changed address as the party will have specified by written notice, provided that any notice of change
of address will be effective only upon actual receipt. Upon request by a party providing notice, a party receiving notice shall
confirm receipt of such notice, such confirmation not to be unreasonably withheld, conditioned, or delayed.

 

ARRAYJET:

 

Arrayjet Ltd

Stobo House

Roslin

EH25 9RE

United Kingdom

Attn: [***]

Email: [***]

 

with a copy to:

 

Rooney Nimmo

8 Walker Street

Edinburgh EH3 7LA

United Kingdom

Attention: [***]

Email: [***]

 

Licensee:

Immunome, Inc.

665 Stockton Drive

Suite 300

Exton, PA 19341

Attn: [***]

Email: [***]

 

with a copy to:

 

Duane Morris LLP

30 South 17th Street

Philadelphia, PA 19103-4196

Attention: [***]

Email: [***]

 

    12

     

    

 

Section 15.                
Confidentiality.

 

A.                
The parties hereto agree to keep any information identified as confidential by the disclosing party confidential using methods
at least as stringent as each party uses to protect its own confidential information and, in any event, using no less than reasonable
care. “Confidential Information” will include the specific terms (but not the existence) of this Agreement,
Licensee’s Development Reports, Royalty Reports and forecasts, sublicenses, non-public information relating to the Licensed
Patents and all non-public information concerning them (including without limitation all know-how, research results and similar
non-public information held by ARRAYJET) and any other information either (i) marked confidential or accompanied by correspondence
indicating such information is exchanged in confidence between the parties, or (ii) that is, or should be, reasonably understood
to be otherwise confidential to a party. Except as may be authorized in advance in writing by ARRAYJET, Licensee will only grant
access to ARRAYJET’s Confidential Information to its sublicensee(s); those employees of Licensee and its sublicensee (s)
or potential sublicensee(s) who are directly involved in research relating to Immunome’s Area of Interest; and its directors,
prospective advisors, and prospective investors, who have a genuine commercial need to access ARRAYJET’s Confidential Information.
Licensee will require its sublicensee(s) and all such employees and other persons and entities to be bound by terms of confidentiality
no less restrictive than those set forth in this clause 15. Licensee and its sublicensee(s) will not use any Confidential Information
to ARRAYJET’s detriment, including, but not limited to, claiming priority to the Licensed Patents in any patent prosecution.

 

B.                 
The confidentiality obligations set forth above apply to all or any part of the Confidential Information disclosed hereunder
except to the extent that: (i) the receiving party can show by competent evidence that it possessed the information prior to its
receipt from the disclosing party; (ii) the information was already available to the public or became so through no fault of the
receiving party; (iii) the information is subsequently disclosed to the receiving party by a third party that has the right to
disclose it free of any obligations of confidentiality; (iv) the information is required by law, rule, regulation, or judicial
process to be disclosed (if such requirement arises, the receiving party will, prior to any such disclosure and to the extent legally
permitted, promptly notify the disclosing party and provide assistance in any reasonable effort to obtain confidential treatment
with respect to, or otherwise limit, qualify, or avoid, such disclosure); or (v) [***] have elapsed from the expiration or termination
of this Agreement; provided, however, that with respect to Confidential Information that a disclosing party identifies as a trade
secret, the confidentiality obligations of this clause 15 shall continue notwithstanding any expiration or termination of this
Agreement for as long as the disclosing party reasonably identifies such Confidential Information as a trade secret.

 

Section 16.               Miscellaneous.
This Agreement will be governed by and construed in all respects in accordance with the laws of the State of Delaware. If any
provisions of this Agreement are or will come into conflict with the laws or regulations of any jurisdiction or any
governmental entity having jurisdiction over the parties or this Agreement, those provisions will be deemed automatically
deleted, if such deletion is allowed by relevant law, and the remaining terms and conditions of this Agreement will remain in
full force and effect. If such a deletion is not so allowed or if such a deletion leaves terms thereby made clearly illogical
or inappropriate in effect, the parties agree to substitute new terms as similar in effect to the present terms of this
Agreement as may be allowed under the applicable laws and regulations. The parties hereto are independent contractors and not
joint venturers or partners.

 

    13

     

    

 

Section 17.                
Integration; Execution.

 

A.                
This Agreement constitutes the full understanding between the parties with reference to the subject matter hereof, and no
statements or agreements by or between the parties, whether orally or in writing made prior to or at the signing hereof, will vary
or modify the written terms of this Agreement. Neither party will claim any amendment, modification, or release from any provisions
of this Agreement by mutual agreement, acknowledgment, or otherwise, unless such mutual agreement is in writing, signed by the
other party, and specifically states that it is an amendment to this Agreement, or where such amendment, modification or release
is otherwise provided for herein.

 

The persons signing on behalf of ARRAYJET
and Licensee hereby warrant and represent that they have authority to execute this Agreement on behalf of the party for whom they
have signed. This Agreement may be executed in one or more counterparts by the parties by signature of a person having authority
to bind the party, each of which when executed and delivered by facsimile, electronic transmission, or by mail delivery, will be
an original and all of which will constitute but one and the same Agreement. The parties agree this Agreement may be electronically
signed and that the electronic signatures appearing on this Agreement are the same as handwritten signatures for the purposes of
validity, enforceability and admissibility.

 

[Signature page follows]

 

    14

     

    

 

IN WITNESS WHEREOF, the parties hereto have duly executed this
Agreement on the Effective Date.

 

	 	ARRAYJET LIMITED
	 	 
	 	By:	/s/ Iain McWilliam
	 	 	Iain McWilliam
	 	 	Chief Executive Officer
	 	 
	 	IMMUNOME, INC
	 	 
	 	By:	/s/ Michael Morin
	 	 	Michael Morin
	 	 	Chief Scientific Officer

 

    15

     

    

 

APPENDIX A

 

A.                
“Date of First Commercial Sale” means the date when Licensee’s cumulative earned royalties paid
to ARRAYJET pursuant to clause 4D exceeds one U.S. dollar ($1).

 

B.                 
“Development Report” means a written account of Licensee’s utilization of the Licensed Patents
and Licensed Know-how to develop Immunome’s Area of Interest within the terms of this Agreement and having at least the information
specified on Appendix D to this Agreement.

 

C.                 
“Immunome’s Area of Interest” means the screening of human derived hybridomas and antibodies or
derivatives thereof against cell lysate libraries where the antigen(s) of interest are unknown.

 

D.                
“Installation Acceptance Date” means the date on which instrumentation is installed by ARRAYJET at the
location specified by the Licensee and the Licensee indicates in writing to ARRAYJET that it has accepted that the instrument has
been installed.

 

E.                 
“Intellectual Property Rights” means patents, rights to inventions, supplementary protection certificates,
copyright and related rights, trade marks and services marks, trade names and domain names, rights in get-up, goodwill and the
right to sue for passing off and unfair competition, rights in designs, rights in computer software, database rights, rights to
preserve the confidentiality of information (including know-how and trade secrets) and any other intellectual property rights,
including all applications for (and rights to apply for and be granted) renewals or extensions of, and rights to claim priority
from, such rights and all similar or equivalent rights or forms of protection which subsist or will subsist, now or in the future,
in any part of the world.

 

F.                 
“Licensed Know-how” means the know-how identified at Part 2 of Appendix B.

 

G.                
“Licensed Field” is limited to the field of antibody therapy.

 

H.                
“Licensee IPR” means all Intellectual Property Rights generated at any time by or on behalf of the Licensee
or any sub-licensee in connection with the exercise of the License, including any Intellectual Property Rights comprised in or
relating to any of the Licensee Results.

 

I.                   
“Licensed Patents” means those patents and patent applications listed on Appendix B attached hereto,
and any divisional, continuation (but not, continuation-in-part), or reexamination application thereof, and each patent that issues
or reissues from any patent application included on Appendix B, but solely to the extent Licensee timely reimburses ARRAYJET
for the Patent Costs related thereto as outlined in clause 4F.

 

J.                   
“Licensee Results” means all technical data, know-how, computer software, notes, chemical compounds,
biological material, models, prototypes, specimens, drawings, reports and information, all documents concerning regulatory submissions
and any improvements, generated at any time by or on behalf of the Licensee or any sub-licensee in connection with the development,
use, manufacture, supply or marketing of the Licensed Patents and Licensed Know-how.

 

K.                
“Licensed Territory” means the USA, the United Kingdom, China, Germany and Japan.

 

L.                 
“MSA” means the Master Services Agreement entered into on the 8th November 2016 between Arrayjet and
Immunome (terms as defined therein).

 

M.               
“Net Sales” means [***]:

 

    A-1

     

    

 

		a.	[***];

 

		b.	[***];

 

		c.	[***];

 

		d.	[***];

 

		e.	[***]; and

 

		f.	[***].

 

N.                
“Non-Commercial Research Purposes” means use for academic research purposes or other not-for-profit or
scholarly purposes not involving the performance of services for a fee or the production or manufacture of products for sale to
third parties.

 

O.                
“Products” means any and all products that incorporate, comprise, employ or are in any way produced by
the practice of an invention claimed in the Licensed Patents, or the manufacture, use, sale, offer for sale, importation, or marketing
of which would otherwise constitute infringement of any claims of the Licensed Patents.

 

P.                 
“Third Party Royalties” means any consideration Licensee or a sublicensee owes to one or more third parties
pursuant to one or more licenses to Intellectual Property Rights entered into by Licensee or the sublicensee that is determined
to be necessary to avoid infringement of such Intellectual Property Rights in the making, having made, using, selling, offering
for sale, or importing of any Product, or to avoid infringement-related litigation with respect to the making, having made, using,
selling, offering for sale, or importing of any Product.

 

    A-2

     

    

 

APPENDIX B

 

[***]

 

    B-1

     

    

 

APPENDIX C

 

ARRAYJET ROYALTY REPORT

 

[***]

 

    C-1

     

    

 

APPENDIX D

 

DEVELOPMENT REPORT

 

[***]

 

    D-1

     

    

 

APPENDIX E

 

RESERVED

 

    E-1

     

    

 

APPENDIX F

 

EXAMPLE EXCLUSIVITY AND LICENSE FEE PAYMENT
MECHANISM

 

[***]

 

    F-1

     

    

 

AMENDMENT
TO LICENSE AGREEMENT

 

This Amendment to License
Agreement (this “Amendment”), is entered into as of the 10th of July, 2020, between Arrayjet Limited, a company incorporated
in Scotland (“ARRAYJET”), and Immunome, Inc., a corporation organized and existing under the laws of the State of Delaware
(“Licensee”).

 

Background

 

The parties entered
into an Exclusive License Agreement effective as of June 28, 2019 (the ‘License Agreement”), and now desire to amend
certain provisions thereof. Capitalized terms used in this Amendment without definition shall have the respective meanings assigned
to them in the License Agreement.

 

NOW, THEREFORE, in
consideration of the premises and covenants set forth herein, and intending to be legally bound hereby, the parties hereto agree
as follows:

 

1.                  
Amendment to Section 4(D) Section 4(D) of the License Agreement is hereby amended so as to add the following Subsection
4(D)(iii) thereto:

 

(iii)       Notwithstanding
anything to the contrary elsewhere in this Section 4(D), the royalty for Net Sales of Products by any sublicensee under an agreement
between Licensee and such sublicensee entered into [***] for any Products (“Other Net Sales”) shall be [***] of the
royalty actually paid by the sublicensee to Licensee with respect to such Products. Accordingly, for purposes of calculating the
royalties under Section 4(D)(i)-(iii), Other Net Sales shall be disregarded and excluded from the definition of Net Sales. In addition,
for purposes of calculating royalties under this Section 4(D) with respect to Other Net Sales, the royalty deduction allowance
in the first paragraph of Section 4(D) shall not be applicable.

 

2.                  
Effect of Amendment. The parties acknowledge and agree that all of the terms, provisions. covenants and conditions
of the License Agreement shall hereafter continue in full force and effect in accordance with the terms thereof, except to the
extent amended herein.

 

3.                  
Governing Law. This Amendment and all dispute, arising out of or relating hereto shall be governed by and construed
under the laws of the State of Delaware, without giving effect to the principle of conflicts of laws.

 

4.                  
Counterparts. This Agreement may be executed in one or more counterparts with the same effect as if all of the parties
had signed the same document. All counterparts shall be construed together and shall constitute one and the same instrument. Executed
counterpart of this Agreement may be delivered by electronic or facsimile transmission with the same effect as if delivered personally.

 

    Page 1 of 2

     

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Amendment to be duly executed and delivered by their proper and duly authorized officers as
of the day and year first above written.

 

	 	IMMUNOME, INC.
	 	 
	 	By:	/s/ Purnanand Sarma
	 	Name:   Purnanand D. Sarma
	 	Title:     President & CEO
	 	 
	 	ARRAYJET LIMITED
	 	 
	 	By:	/s/ Iain McWilliam
	 	Name:   Iain McWilliam
	 	Title:     Chief Executive Officer

 

    Page 2 of 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}]]